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In 1969, Graham and Oppenheimer introduced the term multiple system
atrophy (MSA) to denote a neurodegenerative disease characterized clinically
by varying combinations of autonomic, parkinsonian, cerebellar or pyramidal
symptoms or signs, and neuropathologically by cell loss and gliosis in the basal
ganglia and olivopontocerebellar system. They deserve recognition for having
identified as a single entity a disease that previously had been reported under
the rubrics of olivopontocerebellar atrophy, idiopathic orthostatic hypotension,
Shy-Drager syndrome and striatonigral degeneration depending upon the clin-
ical presentation.
This special issue of Journal of Neural Transmission contains the invited
lectures presented as part of the Second International Meeting on MSA in Rome
on June 17–18, 2004. This meeting followed a previous one dedicated to this
challenging neurodegenerative disease that had been held in London in 1997.
Since the meeting of investigators concerned with MSA in 1997, several
new advances in our understanding of the cellular pathology and clinical fea-
tures of MSA have been reported. In the late nineties a-synuclein was re-
cognized as a major component of glial cytoplasmic inclusions (GCIs), which
represent the specific inclusion pathology found in the brain of patients with
MSA regardless of clinical presentation (Spillantini et al., 1998). Based upon
these developments in molecular pathogenesis, MSA has been firmly estab-
lished as a-synucleinopathy along with Parkinson’s disease and dementia with
Lewy bodies.
In parallel with improved understanding of molecular pathogenesis, recog-
nition of MSA as a clinical entity greatly improved following the introduction
of new diagnostic criteria. Quinn first proposed in 1989 a list of diagnostic
criteria (Quinn, 1989). He divided MSA patients into two major categories:
those presenting with predominantly parkinsonian signs (‘‘MSA-SND’’) and
those with predominant cerebellar involvement (‘‘MSA-OPCA’’). Within each
of these groups patients were labelled as clinically possible or probable accord-
ing to the extent to which multiple systems were involved. Cases were classified
as definite only when neuropathological confirmation was obtained. These
purely clinical criteria were revised in 1994 to include evidence of abnormal
sphincter EMG (Quinn, 1994). In the late nineties a number of pitfalls asso-
ciated with the Quinn criteria were identified. These were: (1) the need for
rigorous criteria for orthostatic hypotension; (2) the importance of urinary
incontinence for diagnosis; (3) abnormal sphincter EMG had been reported in
other disorders, hence it was not specific for MSA; and (4) redundancy in the
classification.
New diagnostic criteria were therefore developed by a consensus conference
based on four clinical domains, including autonomic and urinary dysfunction
(which has now a central role in classifying a patient as probable MSA), par-
kinsonism, cerebellar dysfunction and corticospinal tract dysfunction (Gilman
et al., 1999). The two motor presentations of MSA (parkinsonism and cerebel-
lar ataxia) were designated MSA-P and MSA-C, replacing the previous terms
MSA-SND and MSA-OPCA. The consensus criteria have since been widely
established in the research community as well as movement disorders clinics.
A retrospective evaluation of the consensus criteria showed excellent positive
predictive values for both possible and probable MSA. However, sensitivity for
probable MSA was suboptimal (Osaki et al., 2002). Whether the consensus
criteria will improve recognition of MSA patients, especially in early disease
stages, needs to be investigated by prospective surveys with pathological con-
firmation in as many cases as possible. As magnetic resonance imaging (MRI)
studies have demonstrated findings relatively specific to MSA, the consensus
criteria should be updated to include MRI, and possibly other imaging mo-
dalities such as positron emission tomography. Plans are currently being devel-
oped to convene a further consensus meeting in the near future.
Although therapeutic options are limited at present, there is hope for devel-
opment of treatments for this devastating illness. Two European (EMSA-SG,
NNIPPS) and one North-American (NAMSA-SG) research initiatives are pres-
ently functioning, and in two cases already conducting, multicentre intervention
trials in MSA. These trials hopefully will change our approach to MSA.
Furthermore, prospective clinical and laboratory data concerning disease pro-
gression will become available, allowing us to reliably identify variables that
predict survival. Surrogate markers of the disease process will be identified,
allowing the planning of future phase III intervention trials more effectively. To
this regard, a specific rating instrument (Unified MSA Rating Scale, UMSARS),
including a video teaching tape, has been developed by the EMSA-SG (Wenning
et al., 2004) to standardize severity assessments in specialized clinics and
research programs worldwide.
A number of animal models (using local and systemic neurotoxins) have
become available as test beds for preclinical intervention studies (Scherfler
et al., 2000; Ghorayeb et al., 2000). Recent transgenic mouse models over-
expressing human wild-type a-synuclein in oligodendrocytes also mimic the
molecular pathology of MSA, including the accumulation of GCIs in the glia
(Kahle et al., 2002; Stefanova et al., 2005; Yazawa et al., 2005). Work along
these lines will lead to a better comprehension of the pathopysiology of this
disorders and, hopefully, to a number of candidate neuroprotective agents ready
for evaluation during the next decade.
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